bezafibrate has been researched along with Neoplasms in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brown, PJ; Henke, BR; Sternbach, DD; Willson, TM | 1 |
| Arellano, ML; Boggon, TJ; Brat, DJ; Chen, GZ; Chen, J; Chen, PR; DeBerardinis, RJ; Elf, S; Fan, J; Gu, TL; He, C; Hitosugi, T; Hurwitz, SJ; Ji, Q; Jiang, L; Kang, HB; Kang, S; Khoury, HJ; Khuri, FR; Lee, BH; Lei, Q; Li, Y; Lin, R; Lonial, S; Mao, H; Mitsche, M; Seo, JH; Shan, C; Sudderth, J; Tucker, M; Wang, D; Wu, S; Xie, J; Ye, K; Zhang, L; Zhang, S; Zhou, L | 1 |
| Brenner, R; Gerber, Y; Goldenberg, I; Hasin, T; Iakobishvili, Z; Klempfner, R; Kornowski, R; Shlomo, N | 1 |
2 review(s) available for bezafibrate and Neoplasms
| Article | Year |
|---|---|
The PPARs: from orphan receptors to drug discovery.
Topics: Animals; Diabetes Mellitus; Drug Design; Humans; Hyperlipidemias; Hypertension; Inflammation; Ligands; Models, Molecular; Neoplasms; Nuclear Proteins; Obesity; Receptors, Cytoplasmic and Nuclear; Transcription Factors | 2000 |
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Humans; Lipogenesis; Neoplasms; Oxidative Stress; Pentose Phosphate Pathway; Phosphogluconate Dehydrogenase; Protein Serine-Threonine Kinases; Ribulosephosphates; Signal Transduction | 2015 |
2 other study(ies) available for bezafibrate and Neoplasms
| Article | Year |
|---|---|
Topics: Animals; Bezafibrate; Disease Models, Animal; Energy Metabolism; Humans; Immunotherapy; Lymph Nodes; Mice; Mitochondria; Neoplasms; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Programmed Cell Death 1 Receptor; Reactive Oxygen Species; T-Lymphocytes; T-Lymphocytes, Cytotoxic | 2017 |
Association of Bezafibrate Treatment With Reduced Risk of Cancer in Patients With Coronary Artery Disease.
Topics: Bezafibrate; Cholesterol, HDL; Coronary Artery Disease; Female; Fibrinogen; Humans; Hypolipidemic Agents; Israel; Lipids; Male; Middle Aged; Neoplasms; Registries; Risk Reduction Behavior; Triglycerides | 2019 |